stockrow
Saturday 7 November 2026
Export AVTX’s income statement to Excel — free account
Avalo Therapeutics, Inc.
AVTX Healthcare Biotechnology
Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024.
- Revenue
- −70.1%
- EPS
- +56.8%
- Free cash flow
- +75.7%
Quarter to June 2026, against a year earlier
6.95
0.32
+4.83%
Follow AVTX
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 1 | 5 | 3 | 3 | 5 | 3 | 4 | 2 |
P/E ratio |
0.00 | 7.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 2.21 | 16.14 | 34.47 | 26.42 | 31.72 | 2.61 | 3.66 | 61.16 | 195.21 |
Altman Z-Score |
(24.87) | 2.17 | (2.21) | 3.70 | (5.20) | (5.46) | (15.47) | (26.23) | (2.77) | (2.13) |
Altman Z″-Score (non-manufacturers) |
(56.73) | (0.36) | (7.90) | (10.85) | (21.47) | (13.68) | (38.60) | (59.06) | 2.57 | (8.95) |
P/FCF ratio |
0.00 | 4.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | 46.89 | (3.81) | (2.51) | (5.31) | (3.40) | (2.90) | (3.38) | 13.36 | — |
P/Operating CF |
(2.14) | (24.06) | (57.40) | (138.46) | (12.31) | (10.01) | (11.95) | (2.55) | (5.07) | (17.09) |
P/B ratio |
38.36 | 2.20 | 5.42 | 11.08 | 7.21 | 7.42 | 0.00 | 0.96 | 0.57 | 2.93 |
Price to Tangible BV |
38.36 | 0.00 | 41.53 | 55.97 | 20.66 | 19.83 | 0.00 | 0.00 | 0.62 | 3.36 |
EV/Sales |
0.00 | 2.16 | 16.81 | 35.07 | 24.21 | 27.88 | 2.68 | 5.80 | (37.51) | 125.56 |
EV/EBITDA |
0.00 | 4.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.68 | 0.00 |
EV/Operating CF |
(0.40) | 4.78 | (37.76) | (12.37) | (4.00) | (2.12) | (1.81) | (0.36) | 0.95 | (3.04) |
EV/FCF |
(0.39) | 4.78 | (31.99) | (12.20) | (3.99) | (2.12) | (1.80) | (0.36) | 0.95 | (1.28) |
Quick Ratio |
1.22 | 0.86 | 0.64 | 1.36 | 1.53 | 2.99 | 0.68 | 1.64 | 19.42 | 7.60 |
Current Ratio |
1.31 | 0.96 | 0.84 | 1.46 | 1.71 | 3.11 | 0.74 | 1.82 | 19.96 | 8.14 |
Net Debt/EBITDA |
0.17 | (0.17) | (0.13) | 0.95 | 0.22 | 0.27 | (0.01) | 0.35 | 1.97 | 1.36 |
Debt/Assets |
40.80% | 0.00% | 20.40% | 3.08% | 6.94% | 40.93% | 40.42% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
11.37 | 0.00 | 0.69 | 0.05 | 0.12 | 1.42 | (1.24) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.08 | 1.15 | 0.12 | 0.13 | 0.17 | 0.09 | 0.32 | 0.07 | 0.01 | 0.00 |
Operating CF/Net income |
0.88 | 1.62 | 0.08 | 1.19 | 0.64 | 0.84 | 0.64 | 0.97 | 1.40 | 0.66 |
Capex/Depreciation |
(1.30) | (0.04) | (0.08) | (0.05) | (0.03) | (0.05) | (0.06) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(34.64) | 578.75 | (2,170.46) | (133.04) | (1,489.63) | (34.35) | (8.98) | (8.00) | — | — |
| (247.87%) | 55.38% | (164.27%) | (76.72%) | (278.79%) | (354.20%) | (684.77%) | 1,747.11% | (50.06%) | (72.43%) | |
| (120.11%) | 32.00% | (70.85%) | (30.22%) | (159.02%) | (136.12%) | (73.35%) | (116.06%) | (40.91%) | (58.58%) | |
ROIC |
0.00% | 34.20% | (89.99%) | (92.94%) | (526.72%) | (4,013.58%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1,181.52%) | (2,097.73%) | 1,083.03% | (229.24%) | (512.63%) | (188.96%) | 1,267.36% | (549.36%) | (26.39%) | (84.33%) |
Average Days of Receivables |
41.94 | 93.37 | 315.98 | 283.45 | 238.92 | 324.50 | 38.80 | 25.80 | 505.70 | 0.00 |
Research and Development Expense of Revenue |
880.30% | 15.72% | 82.33% | 174.27% | 480.56% | 1,108.47% | 173.44% | 716.42% | 5,541.27% | 84,888.14% |
Selling, General and Administrative Expense of Revenue |
614.33% | 30.60% | 157.31% | 171.95% | 294.95% | 456.80% | 114.74% | 535.34% | 3,909.52% | 38,813.56% |
Intangible Assets out of Total Assets |
0.00 | 0.75 | 0.26 | 0.47 | 0.37 | 0.18 | 0.43 | 0.50 | 0.07 | 0.09 |
Share Based Compensation of Revenue |
147.00% | 4.16% | 34.59% | 37.51% | 101.30% | 151.39% | 41.85% | 180.72% | 1,326.98% | 23,086.44% |
Graham Net Nets |
0.01 | (0.07) | (0.24) | 0.01 | 0.04 | 0.03 | (0.59) | (0.75) | 1.59 | 0.30 |
Graham Number |
0.00 | 11,041.74 | 0.00 | 0.00 | 0.00 | 0.00 | 2,585.36 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(209.78%) | 12.99% | (35.41%) | (4.90%) | (32.71%) | (47.17%) | (88.80%) | (4,352.97%) | (1,873.96%) | (33.65%) |
Free Cash Flow Yield |
(183.96%) | 20.47% | (3.26%) | (8.34%) | (22.94%) | (41.47%) | (57.03%) | (435.05%) | (64.29%) | (50.25%) |
Revenue per Share |
371.94 | 4,345.80 | 576.10 | 450.03 | 287.51 | 154.23 | 460.48 | 6.93 | 0.10 | 0.00 |
Operating CF per Share |
(4,701.00) | 1,965.44 | (256.40) | (1,275.62) | (1,739.87) | (2,025.49) | (682.42) | (110.48) | (11.08) | (3.84) |
Capex per Share |
(11.26) | (3.64) | (46.26) | (17.47) | (2.70) | (3.23) | (2.42) | 0.09 | 0.00 | 0.00 |
Free Cash Flow per Share |
(4,712.26) | 1,961.80 | (302.66) | (1,293.09) | (1,742.58) | (2,028.71) | (684.85) | (110.39) | (11.08) | (3.84) |
Cash per Share |
1,657.77 | 386.58 | 874.18 | 750.39 | 813.61 | 1,561.03 | 336.40 | 26.71 | 30.40 | 7.34 |
Shareholders Equity per Share |
66.77 | 4,353.06 | 1,713.75 | 1,399.71 | 1,054.16 | 659.49 | (278.44) | 26.30 | 30.06 | 6.20 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
66.77 | 4,353.06 | 1,713.75 | 1,399.71 | 1,054.16 | 659.49 | (278.44) | 26.30 | 30.06 | 6.20 |
Free Cash Flow |
(14.61) | 12.56 | (3.69) | (19.40) | (40.60) | (71.00) | (26.85) | (30.65) | (49.06) | (51.46) |
Working Capital |
1.35 | (0.42) | (4.28) | 5.56 | 10.78 | 41.96 | (5.70) | 3.78 | 131.93 | 92.35 |
Capital Expenditures |
(0.03) | (0.02) | (0.56) | (0.26) | (0.06) | (0.11) | (0.09) | 0.03 | — | — |
Net Current Asset Value |
0.10 | (4.27) | (27.41) | 2.61 | 6.81 | 4.71 | (27.87) | (5.29) | 121.19 | 71.88 |
EV/EBIT |
0.00 | 4.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.68 | 0.00 |
Capex to Sales |
0.03 | 0.00 | 0.08 | 0.04 | 0.01 | 0.02 | 0.01 | (0.01) | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 4.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.62 | 12.63 | 11.45 | 3.76 | 1.15 | 0.91 | 0.65 | 3.00 | 0.14 | 0.75 |
Cash ROIC |
(189.72%) | 41.39% | (8.04%) | (58.14%) | (87.21%) | (64.23%) | (170.36%) | (208.25%) | (18.33%) | (28.36%) |
Accounts Receivable Turnover |
0.30 | 7.68 | 1.07 | 1.19 | 1.39 | 1.18 | 5.37 | 1.87 | 1.18 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.55 | 2.38 | (0.32) | 0.13 | 0.50 | 1.10 | 0.77 | (1.00) | 0.00 |
Inventory Turnover |
— | 1.82 | 9.32 | (3.34) | 24.69 | 72.73 | 118.41 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 745.96 | 161.88 | (1,338.55) | 3,131.70 | 824.74 | 306.33 | 126.78 | (282.23) | 0.00 |
Days of Inventory on Hand |
— | 219.48 | 35.59 | (13.72) | 3.65 | 9.30 | 2.13 | 0.00 | 0.00 | — |
Average Receivables |
3.78 | 3.62 | 6.60 | 5.66 | 4.81 | 4.59 | 3.36 | 1.03 | 0.37 | — |
Average Payables |
0.84 | 1.15 | 1.37 | 1.76 | 2.33 | 2.97 | 3.13 | 1.66 | 0.36 | 0.21 |
Average Inventory |
— | 0.35 | 0.35 | 0.17 | 0.01 | 0.02 | 0.03 | — | — | — |
Average Assets |
13.71 | 24.29 | 56.53 | 53.18 | 39.93 | 61.98 | 56.79 | 27.18 | 85.86 | 133.60 |
Average Common Equity |
6.65 | 14.03 | 24.38 | 20.95 | 22.78 | 23.82 | 6.08 | (1.81) | 70.17 | 108.04 |
Columns are period end dates · fundamentals updated 26 Oct 2026